Continued Benefit, More Toxicity With Osimertinib-Chemo

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.

Related Keywords

Netherlands ,Peru ,Lima ,Amsterdam ,Noord Holland ,Natalia Isabel Valdiviezo Lama ,Netherlands Cancer Institute ,Drug Administration ,National Institute Of Neoplastic Diseases ,European Lung Cancer Congress ,National Institute ,Neoplastic Diseases ,Medscape Medical News ,Joop De Langen ,Non Small Cell Lung Cancer ,Nsclc ,Lung Cancer ,Ung Carcinoma ,Ancer Of The Lung ,Chemotherapy ,Toxicology ,Toxicity ,Poisoning ,Toxins ,Platinum ,Biologic Therapy ,Iologics ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Small Cell Lung Cancer ,At Cell Lung Cancer ,Clc ,Metastasis ,Etastatic Carcinoma ,Metastatic Cancer ,Metastases ,Cancer ,